Biomarker Correlation in Obesity and Insulin Resistance (Observational)

• Study Objective: To assess whether circulating MOTS-c concentrations differ between lean controls and adults with obesity, and how those levels correlate with inflammatory and metabolic markers (PubMed, 2025).

• Methodology: A comparative human cohort study evaluating 22 lean control participants against 32 adult participants with obesity. Baseline metabolic metrics, insulin resistance indicators (HOMA-IR), and blood plasma MOTS-c levels were measured (PubMed, 2025).

• Key Findings: * Circulating MOTS-c levels were significantly higher in the cohort with obesity compared to the lean control group ($273 \pm 56\text{ pg/mL}$ vs. $223 \pm 50\text{ pg/mL}$) (PubMed, 2025).

  • Statistical modeling showed that BMI and HOMA-IR independently predicted elevated MOTS-c levels, exhibiting a sharp, non-linear spike once insulin resistance markers passed a specific threshold ($\sim 6.6\text{ mmol/L} \times \mu\text{U/mL}$) (PubMed, 2025).

• Conclusion: The researchers concluded that elevated circulating MOTS-c in insulin-resistant states represents a compensatory metabolic response. The body appears to upregulate its natural production of MOTS-c to combat localized cellular stress and mitochondrial dysfunction (PubMed, 2025).

References

Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., Joly, J. H., Mitchell, C. J., Cameron-Smith, D., Cohen, P., & Lee, C. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), 470. https://doi.org/10.1038/s41467-020-20790-0

Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. (2025). Preclinical & Biomarker Research Registry, (PMID: 41551324).